Greenlight Biosciences Holdings Pbc's ROA from the first quarter of 2023 to the first quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Greenlight Biosciences Holdings Pbc's ROA in the first quarter of 2023?
Greenlight Biosciences Holdings Pbc recorded a cumulative net loss of $-157 million during 12 months ending in the first quarter of 2023, resulting in a negative return on assets (ROA) of -122.3%.

However, within the Healthcare sector 1018 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2023 quarter, so far to 5257, from total ROA ranking in the fourth quarter of 2022 at 6072.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter
Y / Y Total Assets Change	-6.44 %	-38.42 %	-37.07 %	-62.18 %	67.94 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-157	-167	-163	-154	-129
Return On Assets (TTM)	-122.3 %	-127.91 %	-105.93 %	-87.34 %	-59.62 %
GRNA's Total Ranking	# 5257	# 6072	# 5429	# 5072	# 4358
Total Assets (TTM) in million	115	149	153	98	122
Seq. Total Assets Change	-23.12 %	-2.35 %	55.05 %	-19.62 %	-49.4 %
Seq. Net Income Change	-	-	-	-	-

GRNA's 5 Years Annual ROA >> Back to GRNA Management Effectiveness >> Compare GRNA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 163
Sector	# 1019
Overall	# 5145

Return On Assets Statistics
High	Average	Low
-20.49 %	-95.16 %	-149.6 %
(Mar 31 2022)		(Sep 30 2022)

Financial Statements
Greenlight Biosciences Holdings Pbc's Assets	$ 115 million	GRNA's Balance sheet
Greenlight Biosciences Holdings Pbc's Income	$ -28 million	Quarterly GRNA's Income Statement
GRNA's Income by Division		See GRNA's Income by Division

Annual Return On Assets	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	FY	FY	FY
Y / Y Total Assets Change	-28.2 %	61244.97 %	-	-	-
Total Assets in million	149	208	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-167	-15	0	0	0
Annual Return On Assets	-112.12 %	-7.26 %	-	-	-

GRNA's 5 Years Annual ROA >> Back to GRNA Management Effectiveness >> Compare GRNA ROA to its Competitors

More Return On Assets Ratios
GRNA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GRNA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GRNA's Competitors
Subscribers only: Roa for Greenlight Biosciences Holdings Pbc's Suppliers
Subscribers only: Return On Assets for GRNA's Customers

You may also want to know
GRNA's Roi	GRNA's Inventory Turnover Ratio	GRNA's Growth Rates	GRNA's Dividend Comparisons
	GRNA's Profitability Ratios	GRNA's Asset Turnover Ratio	GRNA's Dividend Growth
GRNA's Roe	GRNA's Valuation Ratios	GRNA's Financial Strength Ratios	GRNA's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2023, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.